NCT07121244 - A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2033

Conditions

Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast Cancer

Interventions

DRUG

68Ga-R11228

68Ga-R11228 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions

DRUG

177Lu-R11228

177Lu-R11228 is a lutetium-labeled small molecule radioligand designed to treat tumor lesions

Trial Locations (2)

RECRUITING

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

RECRUITING

Melbourne Theranostic Innovation Centre (MTIC), Melbourne